Developing of trilobatin dihydrochalcone as a new-style of phytochemical agent

Pharmaceutical Regulatory Affairs: Open Access

ISSN: 2167-7689

Open Access

Developing of trilobatin dihydrochalcone as a new-style of phytochemical agent

21st Annual European Pharma Congress

May 20-22, 2019 | Zurich, Switzerland

Mwafaq Ibdah, Bhagwat Nawade and Mossab Yahyaa

Newe Yaar Research Center Agriculture Research Organization, Israel

Posters & Accepted Abstracts: Pharmaceut Reg Affairs

Abstract :

The increasing prevalence of several diseases, like AlzheimerÔ??s disease, obesity, cancer, and diabetes, in humans in recent decades worldwide, accompanied by rising concern regarding the safety of many synthetic chemistrybased pharmaceuticals, has raised public demand for phytochemical-based medicines. This in turn has led to increasing interest in metabolic engineering as an approach to produce such natural products on an industrial scale, which has the potential to decrease production costs of, e.g. desired dihydrochalcones. We note that fruits accumulating high level of phytochemicals including flavonoids and dihydrochalcones that may play a key role in reducing chronic disease risk. We have developed a novel concept to produce a new-style phytochemical agent of benefit for humans by genetic transformation of three characterized genes in plant cells, bacterial, and yeast systems. We have applied a set of molecular and biochemical tools to identified reactions and enzymes leading to the biosynthesis of dihydrochalcones. We recently cloned and biochemically characterized three key enzymes in the dihydrochalcone biosynthesis pathway; a p-coumaroyl-CoA double bond reductase that converts p-coumaroyl- CoA into p-dihydrocoumaroyl-CoA, chalcone synthase that accepted p-dihydrocoumaroyl-CoA, in the presence of malonyl-CoA, leading to production of phloretin, and a specialized phloretin-4'-O-glycosyltransferse which glycosylated phloretin in the presence of UDP-glucose into trilobatin. The production of the phytochemical trilobatin was achived by overexpression of these genes in microbial cell factory. The proof of our concept have open the possibility for developing new-style of natural phytochemical for a growing market of population suffering from "modern" diseases.

Google Scholar citation report
Citations: 499

Pharmaceutical Regulatory Affairs: Open Access received 499 citations as per Google Scholar report

Pharmaceutical Regulatory Affairs: Open Access peer review process verified at publons

Indexed In

arrow_upward arrow_upward